Nielsen Matthew E, Palapattu Ganesh S, Karakiewicz Pierre I, Lotan Yair, Bastian Patrick J, Lerner Seth P, Sagalowsky Arthur I, Schoenberg Mark P, Shariat Shahrokh F
The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA.
BJU Int. 2007 Nov;100(5):1015-20. doi: 10.1111/j.1464-410X.2007.07132.x. Epub 2007 Sep 3.
To examine the association between the interval from the last transurethral resection (TUR) to radical cystectomy (RC) and bladder cancer-specific outcome, as the decision to proceed to RC for an individual patient is complex, and recent reports suggest an interval from diagnosis to RC of >3 months is associated with adverse outcomes.
The records of 592 patients who had RC were reviewed; the interval from the last TUR was analysed as both a continuous and categorical variable (<3 vs >/=3 months). Logistic regression and survival analyses were used to evaluate the association between the interval to RC with pathological characteristics and clinical outcomes.
The mean (sd) actuarial cancer-specific survival was 70.5 (2.3)% and 60.7 (3.2)% at 3 and 7 years, respectively. Overall, the median (range) time from TUR to RC was 1.8 (0.3-11.6) months. The interval to RC analysed as a continuous or categorical variable was not associated with extravesical or nodal disease, lymph node metastases, disease recurrence, overall or cancer-specific survival. The results were similar in the subgroup of 320 patients (54%) with clinically muscle-invasive disease.
These results suggest that a reasonable delay from the last TUR to RC is not independently associated with stage progression or with decreased recurrence-free or disease-specific survival. These findings might have important implications for trial design in the ongoing evaluation of neoadjuvant regimens. Nevertheless, we see no reason to advocate anything less than the timely consideration of definitive treatment for patients with high-risk bladder cancer.
鉴于为个体患者决定是否进行根治性膀胱切除术(RC)较为复杂,且近期报告表明从诊断到RC的间隔时间>3个月与不良预后相关,故本研究旨在探讨从末次经尿道膀胱肿瘤切除术(TUR)至RC的间隔时间与膀胱癌特异性预后之间的关联。
回顾了592例行RC患者的记录;将从末次TUR开始的间隔时间作为连续变量和分类变量(<3个月与≥3个月)进行分析。采用逻辑回归和生存分析来评估至RC的间隔时间与病理特征及临床结局之间的关联。
3年和7年时精算的癌症特异性生存率分别为70.5(2.3)%和60.7(3.2)%。总体而言,从TUR至RC的中位(范围)时间为1.8(0.3 - 11.6)个月。将至RC的间隔时间作为连续变量或分类变量进行分析时,其与膀胱外或淋巴结疾病、淋巴结转移、疾病复发、总生存或癌症特异性生存均无关联。在320例(54%)临床肌层浸润性疾病患者亚组中结果相似。
这些结果表明,从末次TUR至RC的合理延迟与分期进展或无复发生存率或疾病特异性生存率降低无独立关联。这些发现可能对正在进行的新辅助治疗方案评估中的试验设计具有重要意义。然而,对于高危膀胱癌患者,我们认为没有理由不提倡及时考虑确定性治疗。